Search > Lung Cancer
10 Participants NeededMy employer runs this trial

Radiation Therapy for Lung Cancer

JA
Overseen ByJessica Anders
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Indiana University
Must not be taking: Radioactive iodine
Disqualifiers: Prior thoracic radiotherapy, Renal insufficiency, AV block, others
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).

Who Is on the Research Team?

JH

Jordan Holmes, MD

Principal Investigator

Indiana University

Are You a Good Fit for This Trial?

This trial is for people with locally advanced non-small cell lung cancer (NSCLC) who have received standard chemotherapy and radiation. Participants should be able to undergo heart imaging tests. Those with conditions that prevent safe imaging or participation may not be eligible.

Inclusion Criteria

I am scheduled to receive standard chemoradiation therapy for my cancer.
My tumor is close to my heart or may receive a high radiation dose.
Ability to provide written informed consent and HIPAA authorization
See 2 more

Exclusion Criteria

I have received stereotactic body radiotherapy (SBRT).
History of a severe anaphylactic reaction to iodinated contrast (for Coronary computed tomography angiography)
I am currently receiving radioactive iodine therapy.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-Radiotherapy Assessment

Participants undergo PET/CT 18F-Flurpiridaz Rest/Stress Test to assess myocardial blood flow before radiation therapy

1 week
1 visit (in-person)

Radiation Therapy

Participants receive standard of care radiation therapy for NSCLC

6-8 weeks

Post-Radiotherapy Assessment

Participants undergo PET/CT 18F-Flurpiridaz Rest/Stress Test to assess myocardial blood flow 3 months after radiation therapy

1 week
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

What Are the Treatments Tested in This Trial?

Trial Overview

The study uses PET/CT scans with a tracer called 18F-Flurpiridaz and coronary CT angiography (CCTA) to check for heart damage after cancer treatment. It aims to find out how often and how much the heart is affected by these therapies.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: PET/CT 18F-Flurpiridaz Rest/Stress TestExperimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Indiana University

Lead Sponsor

Trials
1,063
Recruited
1,182,000+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.